All News

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.

Martin F. Dietrich, MD, PhD, explains how NALIRIFOX dosing in the NAPOLI 3 trial resulted in lower rates of grade 3/4 neutropenia vs standard therapy for metastatic PDAC.

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

The NAPOLI 3 trial demonstrated that NALIRIFOX improved outcomes for patients with metastatic pancreatic ductal adenocarcinoma compared with the standard of care, nab-paclitaxel and gemcitabine.

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.

Because EVA1 is not expressed in normal cells, there may be less toxicity when targeting it to eliminate glioblastoma-initiating cells.

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were the 3 most prominent ADCs in EGFR-amplified glioblastoma.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventive measures and a collaboration with dermatology.

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.

The Aliya PEF ablation procedure achieved local tumor control in 96% of patients and was well-tolerated with no delays to SOC therapy.

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.

ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.

Data from a phase 1/2 trial demonstrate the potential antitumor activity of FOG-001 in patients with desmoid tumors.

Ron Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.